ANTH Share Price Performance
US$0.001
0.00 (900.00%)
Price US$0.001
Share PriceUS$0.001
Anthera Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ANTH Community Narratives
There are no narratives available yet.
Recent ANTH News & Updates
No updates
Anthera Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2018
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Anthera Pharmaceuticals, Inc. Competitors
Snowflake Analysis
About ANTH
- Founded
- 2004
- Employees
- n/a
- CEO
- WebsiteView website
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.9%
- 3 Months: 8.7%
- 1 Year: 18.4%
- Year to Date: 14.8%
Over the last 7 days, the market has risen 1.2%, driven by gains of 2.4% in the Information Technology sector. As for the past 12 months, the market is up 18%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›